Drug intelligence / Profile preview

Nikord

Development stage: Preclinical
Lead developer: Kian Immune Cell Company
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Oral

Overview

Nikord is a preclinical cord blood-derived natural killer (NK) cell therapy being developed by Kian Immune Cell Company for the treatment of solid tumors. The therapy utilizes allogeneic NK cells isolated and expanded from umbilical cord blood. Its mechanism of action involves the direct destruction of tumor cells through NK cell-mediated cytotoxicity and the subsequent activation of a broader innate immune response. As an "off-the-shelf" product, Nikord aims to provide a readily available cellular immunotherapy option for patients with various oncology-related diseases.

Brand names: Nikord
Other names: NiKord

Beyond the preview

Go deeper on Nikord.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nikord.

Explore the full profile